Skip to main content
. 2011 Jun 22;21(3):118–124. doi: 10.1007/s12471-011-0174-5

Table 3.

Medical strategy after MPS

Low-risk (n = 101) High-risk (n = 96)
Beta-blocker (n, %) 54 (53%) 86 (90%)
Aspirin (n, %) 66 (65%) 69 (72%)
Warfarin (n, %) 31 (31%) 36 (36%)
Statin (n, %) 58 (57%) 88 (92%)

Patients could be on aspirin, warfarin or aspirin and warfarin therapy